Protecting kidneys from damage caused by cisplatin chemotherapy
Official title: Save Kidneys in Cisplatin Chemotherapy by blocking HDAC6
Funded at Rhode Island Hospital · NIH-10841270 · Data updated 2026-11-12
This study is looking at whether blocking a certain protein can help protect your kidneys from damage caused by cisplatin, a chemotherapy drug used to treat cancer, and it aims to find ways to keep your kidneys healthier during treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rhode Island Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $100,000 |
| NIH project number | 1R56DK135540-01 |
| Project ID | NIH-10841270 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving cisplatin chemotherapy and are at risk of kidney damage.
✕Less likely to help
Patients who are not undergoing cisplatin treatment or those with pre-existing severe kidney disease may not benefit from this research.
What this research studies
This research investigates how blocking a specific protein, histone deacetylase 6 (HDAC6), can help prevent kidney injury caused by cisplatin, a common chemotherapy drug used to treat solid tumors. The study aims to understand the mechanisms behind kidney damage during cisplatin treatment and explore the potential of HDAC6 inhibition as a protective strategy. By using animal models, researchers will assess how this approach can reduce kidney damage and improve overall kidney health in patients undergoing chemotherapy.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect patients' kidneys during cisplatin chemotherapy, reducing the risk of kidney injury.
How similar studies have gone: Preliminary studies have shown promise in using HDAC6 inhibition to protect against kidney injury, suggesting that this approach may be effective.
Where this research is happening
-
Rhode Island Hospital
Providence, United States Active
Researchers
- Principal investigator: Zhuang, Shougang — Rhode Island Hospital
- Study coordinator: Zhuang, Shougang
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.